BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One 2015;10:e0124655. [PMID: 25951460 DOI: 10.1371/journal.pone.0124655] [Cited by in Crossref: 33] [Cited by in F6Publishing: 20] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Nakamura H, Oku K, Ogata Y, Ohmura K, Yoshida Y, Kitano E, Fujieda Y, Kato M, Bohgaki T, Amengual O, Yasuda S, Fujimura Y, Seya T, Atsumi T. Alternative pathway activation due to low level of complement factor H in primary antiphospholipid syndrome. Thromb Res 2018;164:63-8. [PMID: 29494857 DOI: 10.1016/j.thromres.2018.02.142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
2 Miyata T, Uchida Y, Yoshida Y, Kato H, Matsumoto M, Kokame K, Fujimura Y, Nangaku M. No association between dysplasminogenemia with p.Ala620Thr mutation and atypical hemolytic uremic syndrome. Int J Hematol 2016;104:223-7. [PMID: 27194432 DOI: 10.1007/s12185-016-2021-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T, Nangaku M. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 2018;22:1088-99. [PMID: 29511899 DOI: 10.1007/s10157-018-1549-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
4 Yamada Y, Abe R, Okano Y, Miyakawa Y. Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome. Intern Med 2017;56:1085-8. [PMID: 28458317 DOI: 10.2169/internalmedicine.56.7862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
5 Wang N, Zeng Q, Zhang R, Xing D, Zhang T. Eradication of solid tumors by chemodynamic theranostics with H2O2-catalyzed hydroxyl radical burst. Theranostics 2021;11:2334-48. [PMID: 33500728 DOI: 10.7150/thno.49277] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
6 Saito D, Watanabe E, Ashida A, Kato H, Yoshida Y, Nangaku M, Ohtsuka Y, Miyata T, Hattori N, Oda S. Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case Report. Crit Care Explor 2019;1:e0008. [PMID: 32166254 DOI: 10.1097/CCE.0000000000000008] [Reference Citation Analysis]
7 Yokoo T, Tanabe A, Yoshida Y, Caaveiro JMM, Nakakido M, Ikeda Y, Fujimura Y, Matsumoto M, Entzminger K, Maruyama T, Okumura CJ, Nangaku M, Tsumoto K. Antibody recognition of complement Factor H reveals a flexible loop involved in Atypical Hemolytic Uremic Syndrome pathogenesis. J Biol Chem 2022;:101962. [PMID: 35452676 DOI: 10.1016/j.jbc.2022.101962] [Reference Citation Analysis]
8 Yamaguchi M, Hori M, Hiroshi N, Maruyama S. Postpartum atypical hemolytic uremic syndrome with complement factor H mutation complicated by reversible cerebrovascular constriction syndrome successfully treated with eculizumab. Thromb Res 2017;151:79-81. [PMID: 28167400 DOI: 10.1016/j.thromres.2017.01.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
9 Mizuno M, Suzuki Y, Ito Y. Complement regulation and kidney diseases: recent knowledge of the double-edged roles of complement activation in nephrology. Clin Exp Nephrol 2018;22:3-14. [DOI: 10.1007/s10157-017-1405-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
10 Fujisawa M, Yasumoto A, Kato H, Sugawara Y, Yoshida Y, Yatomi Y, Nangaku M. The role of anti-complement factor H antibodies in the development of atypical haemolytic uremic syndrome: a possible contribution to abnormality of platelet function. Br J Haematol 2020;189:182-6. [PMID: 31879952 DOI: 10.1111/bjh.16297] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
11 Okabe M, Kobayashi A, Marumoto H, Koike K, Yamamoto I, Kawamura T, Tsuboi N, Yokoo T. Renal Damage in Recurrent Atypical Hemolytic Uremic Syndrome Associated with C3 p.Ile1157Thr Gene Mutation. Intern Med 2021;60:917-22. [PMID: 33087669 DOI: 10.2169/internalmedicine.5716-20] [Reference Citation Analysis]
12 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 2016;20:536-43. [PMID: 27422619 DOI: 10.1007/s10157-016-1276-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
13 Omura T, Watanabe E, Otsuka Y, Yoshida Y, Kato H, Nangaku M, Miyata T, Oda S. Complete remission of thrombotic microangiopathy after treatment with eculizumab in a patient with non-Shiga toxin-associated bacterial enteritis: A case report. Medicine (Baltimore) 2016;95:e4104. [PMID: 27399110 DOI: 10.1097/MD.0000000000004104] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S; Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan. Clinical guides for atypical hemolytic uremic syndrome in Japan. Pediatr Int. 2016;58:549-555. [PMID: 27460397 DOI: 10.1111/ped.13044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.6] [Reference Citation Analysis]
15 Tan PL, Bowes Rickman C, Katsanis N. AMD and the alternative complement pathway: genetics and functional implications. Hum Genomics 2016;10:23. [PMID: 27329102 DOI: 10.1186/s40246-016-0079-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
16 Yamamura T, Nozu K, Ueda H, Fujimaru R, Hisatomi R, Yoshida Y, Kato H, Nangaku M, Miyata T, Sawai T, Minamikawa S, Kaito H, Matsuo M, Iijima K. Functional splicing analysis in an infantile case of atypical hemolytic uremic syndrome caused by digenic mutations in C3 and MCP genes. J Hum Genet 2018;63:755-9. [PMID: 29556035 DOI: 10.1038/s10038-018-0436-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
17 Nakamura H, Anayama M, Makino M, Makino Y, Tamura K, Nagasawa M. Atypical Hemolytic Uremic Syndrome Associated with Complement Factor H Mutation and IgA Nephropathy: A Case Report Successfully Treated with Eculizumab. Nephron 2018;138:324-7. [DOI: 10.1159/000485194] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
18 Saida K, Fukuda T, Mizuno K, Ogura M, Kamei K, Ito S. Pharmacokinetics and Pharmacodynamics Estimation of Eculizumab in a 2-Year-Old Girl With Atypical Hemolytic Uremic Syndrome: A Case Report With 4-Year Follow-Up. Front Pediatr 2019;7:519. [PMID: 31921730 DOI: 10.3389/fped.2019.00519] [Reference Citation Analysis]
19 Yoshida Y, Kato H, Nangaku M. Atypical hemolytic uremic syndrome. Ren Replace Ther 2017;3. [DOI: 10.1186/s41100-016-0088-1] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Matsumoto T, Toyoda H, Amano K, Hirayama M, Ishikawa E, Fujimoto M, Ito M, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Kawamura N, Ikejiri M, Kawakami K, Miyata T, Wada H. Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan. Clin Appl Thromb Hemost 2018;24:1301-7. [PMID: 29695177 DOI: 10.1177/1076029618771750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
21 Yoshida Y, Kato H, Ikeda Y, Nangaku M. Pathogenesis of Atypical Hemolytic Uremic Syndrome. J Atheroscler Thromb 2019;26:99-110. [PMID: 30393246 DOI: 10.5551/jat.RV17026] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
22 Carver JA, Simpson AL, Rathi RP, Normil N, Lee AG, Force MD, Fiocca KA, Maley CE, Dijoseph KM, Goldstein AL, Attari AA, O’malley HL, Zaccaro JG, Mccampbell NM, Wentz CA, Long JE, Mcqueen LM, Sirch FJ, Johnson BK, Divis ME, Chorney ML, Distefano SL, Yost HM, Greyson BL, Cid EA, Lee K, Yhap CJ, Dong M, Thomas DL, Banks BE, Newman RB, Rodriguez J, Segil AT, Siberski JA, Lobo AL, Ellison MD. Functionalized Single-Walled Carbon Nanotubes and Nanographene Oxide to Overcome Antibiotic Resistance in Tetracycline-Resistant Escherichia coli. ACS Appl Nano Mater 2020;3:3910-21. [DOI: 10.1021/acsanm.0c00677] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Yoshida Y, Miyata T, Matsumoto M, Shirotani-Ikejima H, Uchida Y, Ohyama Y, Kokubo T, Fujimura Y. Correction: A Novel Quantitative Hemolytic Assay Coupled with Restriction Fragment Length Polymorphisms Analysis Enabled Early Diagnosis of Atypical Hemolytic Uremic Syndrome and Identified Unique Predisposing Mutations in Japan. PLoS One 2017;12:e0178015. [PMID: 28520790 DOI: 10.1371/journal.pone.0178015] [Reference Citation Analysis]
24 Okumi M, Tanabe K. Prevention and treatment of atypical haemolytic uremic syndrome after kidney transplantation. Nephrology (Carlton) 2016;21 Suppl 1:9-13. [PMID: 26988663 DOI: 10.1111/nep.12776] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]